Comparison of Serum Dkk1 (Dickkopf-1) and Bone Mineral Density in Patients on Bisphosphonate Treatment Vs no Treatment

Journal of Clinical Densitometry

Volumn 16, Issue 1, 2013, Pages 118-124

  Memon, Adeel R ^a   Butler, Joseph S ^a   O'Riordan, Michael V ^a   Guerin, Elizabeth ^a   Dimitrov, Borislav D ^b   Harty, James A ^a  

^a University College Cork and INFANT Centre   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Bisphosphonates; Bone mineral density; DEXA; Dkk1; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DICKKOPF 1 PROTEIN;

AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

AGED; BONE DISEASES, METABOLIC; BONE REMODELING; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OSTEOPOROSIS;

EID: 84873107779     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.07.003     Document Type: Article

References (33)

1. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285(6):785-795. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy.
2. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17(12):1726-1733.
3. Johnell O., Kanis J.A. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004, 15(11):897-902.
4. Cummings S.R., Black D.M., Rubin S.M. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989, 149(11):2445-2448.
5. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359(9319):1761-1767.
6. Moon R.T., Bowerman B., Boutros M., Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296(5573):1644-1646.
7. Pandur P., Maurus D., Kuhl M. Increasingly complex: new players enter the Wnt signaling network. Bioessays 2002, 24(10):881-884.
8. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
9. Miller J.R. The Wnts. Genome Biol 2002, 3(1). REVIEWS3001.
10. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480.
11. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17(1):9-26.
12. Krupnik V.E., Sharp J.D., Jiang C., et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999, 238(2):301-313.
13. Semenov M.V., Zhang X., He X. DKK1 antagonizes Wnt signaling without promotion of LRP6 internalization and degradation. J Biol Chem 2008, 283(31):21427-21432.
14. Ellwanger K., Saito H., Clement-Lacroix P., et al. Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol 2008, 28(15):4875-4882.
15. Mao B., Wu W., Davidson G., et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002, 417(6889):664-667.
16. Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107(4):513-523.
17. Balemans W., Ebeling M., Patel N., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10(5):537-543.
18. Plotkin L.I., Aguirre J.I., Kousteni S., et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005, 280(8):7317-7325.
19. Plotkin L.I., Weinstein R.S., Parfitt A.M., et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104(10):1363-1374.
20. Rizzoli R., Greenspan S.L., Bone G., et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17(11):1988-1996.
21. Cremers S.C.L.M., Pillai G., Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005, 44(6):551-570.
22. Patient safety information about radiation risks. Available at: Accessed July 30, 2012. http://www.radiologyinfo.org.
23. Tonino R.P., Meunier P.J., Emkey R., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85(9):3109-3115.
24. Ravn P., Weiss S.R., Rodriguez-Portales J.A., et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000, 85(4):1492-1497.
25. Voskaridou E., Christoulas D., Xirakia C., et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009, 94(5):725-728.
26. Polyzos S.A., Anastasilakis A.D., Efstathiadou Z., et al. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone. Horm Metab Res 2009, 41(11):846-850.
27. Polyzos S.A., Anastasilakis A.D., Litsas I., et al. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. J Clin Densitom 2010, 13(2):190-196.
28. Rauner M., Sipos W., Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age (Dordr) 2008, 30(4):273-282.
29. Butler J.S., Murray D.W., Hurson C.J., et al. The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res 2010, 11:11.
30. Cranney A., Wells G., Willan A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23(4):508-516.
31. von Knoch F., Jaquiery C., Kowalsky M., et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005, 26(34):6941-6949.
32. Qiang Y.W., Chen Y., Stephens O., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112(1):196-207.
33. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13(2):156-163.